Use of dupilumab as adjuvant therapy in AIT
| Reference | Study type | Allergen | Patients | Main results/aims |
|---|---|---|---|---|
| Corren et al. [60], 2021 | Phase 2, RCT, MC, DBPC | Grass | 103 | Dupilumab may enhance the tolerability of SCIT, but it does not appear to reduce nasal symptoms after challenge when compared to SCIT alone. |
| NCT03682770 [63] | Phase 2, RCT, MC, DBPC | Peanuts | 149 | Number of patients able to complete an exit food challenge with 2,044 mg of cumulative peanut protein. |
| NCT03679676 [64] | Phase 2, RCT, SC, DBPC | Multiallergen OIT | 110 | Number of patients who successfully passed a food challenge for peanut and two other FAs. |
| NCT04148352 [65] | Phase 2, RCT, MC, DBPC | Milk | 40 | Number of patients who received dupilumab plus milk protein OIT vs. placebo plus milk protein OIT, and were able to tolerate a minimum of 2,040 mg (cumulative) of cow’s milk protein during food challenge at week 18. |